NVS logo

Novartis AG (NVS) CAPEX

annual CAPEX:

$3.81B+$1.06B(+38.46%)
December 31, 2024

Summary

  • As of today (August 18, 2025), NVS annual capital expenditures is $3.81 billion, with the most recent change of +$1.06 billion (+38.46%) on December 31, 2024.
  • During the last 3 years, NVS annual CAPEX has risen by +$779.84 million (+25.72%).
  • NVS annual CAPEX is now -27.71% below its all-time high of $5.27 billion, reached on December 31, 2001.

Performance

1-year change

+38.46%

3-year change

+25.72%

5-year change

+64.52%

15-year change

+38.81%

NVS CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

99.59%
NVS annual capital expenditures is higher than 99.59% of companies in Healthcare sector

Range

All-time high

$5.27B
NVS annual capital expenditures is currently -27.71% below its historical high of $5.27 billion

3-year low

$2.24B
NVS annual capital expenditures is currently +70.17% above its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
NVS previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
NVS next annual earnings announcement has not yet been scheduled

OtherNVScash flow metrics

annual FCF

$13.80B
NVS annual free cash flow is $13.80 billion

annual CFO

$17.61B
NVS annual cash flow from operations is $17.61 billion

annual CFI

-$7.51B
NVS annual cash flow from investing activities is -$7.51 billion

annual CFF

-$11.74B
NVS annual cash flow from financing activities is -$11.74 billion

quarterly CAPEX:

$578.99M-$915.01M(-61.25%)
June 30, 2025

Summary

  • As of today (August 18, 2025), NVS quarterly capital expenditures is $578.99 million, with the most recent change of -$915.01 million (-61.25%) on June 30, 2025.
  • Over the past year, NVS quarterly CAPEX has dropped by -$149.01 million (-20.47%).
  • NVS quarterly CAPEX is now -69.38% below its all-time high of $1.89 billion, reached on December 31, 2015.

Performance

3-month change

-61.25%

1-year change

-20.47%

3-year change

-0.69%

5-year change

+26.14%

NVS quarterly CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

98.96%
NVS quarterly capital expenditures is higher than 98.96% of companies in Healthcare sector

Range

All-time high

$1.89B
NVS quarterly capital expenditures is currently -69.38% below its historical high of $1.89 billion

3-year low

$300.00M
NVS quarterly capital expenditures is currently +93.00% above its 3-year low

Earnings dates

Last quarterly earnings report date

Jun 30, 2025
NVS previous earnings announcement was published on Jun 30, 2025

Next quarterly earnings report date

Oct 28, 2025
NVS next earnings announcement is scheduled for Oct 28, 2025

OtherNVScash flow metrics

quarterly FCF

$6.19B
NVS quarterly free cash flow is $6.19 billion

quarterly CFO

$6.77B
NVS quarterly cash flow from operations is $6.77 billion

quarterly CFI

-$2.26B
NVS quarterly cash flow from investing activities is -$2.26 billion

quarterly CFF

-$5.35B
NVS quarterly cash flow from financing activities is -$5.35 billion

TTM CAPEX:

$4.00B-$149.01M(-3.59%)
June 30, 2025

Summary

  • As of today (August 18, 2025), NVS TTM capital expenditures is $4.00 billion, with the most recent change of -$149.01 million (-3.59%) on June 30, 2025.
  • Over the past year, NVS TTM CAPEX has increased by +$652.99 million (+19.49%).
  • NVS TTM CAPEX is now -5.90% below its all-time high of $4.25 billion, reached on September 30, 2016.

Performance

3-month change

-3.59%

1-year change

+19.49%

3-year change

+34.46%

5-year change

+80.56%

NVS TTM CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

99.48%
NVS TTM capital expenditures is higher than 99.48% of companies in Healthcare sector

Range

All-time high

$4.25B
NVS TTM capital expenditures is currently -5.90% below its historical high of $4.25 billion

3-year low

$1.77B
NVS TTM capital expenditures is currently +126.04% above its 3-year low

Earnings dates

Last quarterly earnings report date

Jun 30, 2025
NVS previous earnings announcement was published on Jun 30, 2025

Next quarterly earnings report date

Oct 28, 2025
NVS next earnings announcement is scheduled for Oct 28, 2025

OtherNVScash flow metrics

TTM FCF

$16.89B
NVS TTM free cash flow is $16.89 billion

TTM CFO

$20.89B
NVS TTM cash flow from operations is $20.89 billion

TTM CFI

-$5.34B
NVS TTM cash flow from investing activities is -$5.34 billion

TTM CFF

-$17.28B
NVS TTM cash flow from financing activities is -$17.28 billion

NVS CAPEX Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+38.5%-20.5%+19.5%
3 y3 years+25.7%-0.7%+34.5%
5 y5 years+64.5%+26.1%+80.6%

NVS CAPEX Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+70.2%-61.3%+93.0%-3.6%+126.0%
5 y5-yearat high+70.2%-61.3%+93.0%-3.6%+126.0%
alltimeall time-27.7%+229.4%-69.4%+313.6%-5.9%+1576.5%

NVS CAPEX History

DateAnnualQuarterlyTTM
Jun 2025
-
$578.99M(-61.2%)
$4.00B(-3.6%)
Mar 2025
-
$1.49B(+32.1%)
$4.15B(+8.9%)
Dec 2024
$3.81B(+38.5%)
$1.13B(+41.6%)
$3.81B(+10.0%)
Sep 2024
-
$799.00M(+9.8%)
$3.47B(+3.5%)
Jun 2024
-
$728.00M(-37.0%)
$3.35B(-4.8%)
Mar 2024
-
$1.16B(+47.6%)
$3.52B(+27.8%)
Dec 2023
$2.75B(+22.9%)
$783.00M(+14.6%)
$2.75B(+11.5%)
Sep 2023
-
$683.00M(-24.0%)
$2.47B(+18.4%)
Jun 2023
-
$898.40M(+130.4%)
$2.09B(+17.8%)
Mar 2023
-
$389.91M(-21.7%)
$1.77B(-20.9%)
Dec 2022
$2.24B(-26.1%)
$498.00M(+66.0%)
$2.24B(-17.8%)
Sep 2022
-
$300.00M(-48.5%)
$2.72B(-8.5%)
Jun 2022
-
$583.00M(-32.1%)
$2.98B(-1.5%)
Mar 2022
-
$859.00M(-12.5%)
$3.02B(-0.4%)
Dec 2021
$3.03B(+14.6%)
$982.00M(+77.6%)
$3.03B(-1.6%)
Sep 2021
-
$553.00M(-11.8%)
$3.08B(-2.5%)
Jun 2021
-
$627.00M(-27.9%)
$3.16B(+5.6%)
Mar 2021
-
$870.00M(-15.5%)
$2.99B(+13.1%)
Dec 2020
$2.65B(+14.2%)
$1.03B(+62.7%)
$2.65B(+16.2%)
Sep 2020
-
$633.00M(+37.9%)
$2.28B(+2.8%)
Jun 2020
-
$459.00M(-12.4%)
$2.22B(+0.2%)
Mar 2020
-
$524.00M(-20.8%)
$2.21B(-4.5%)
Dec 2019
$2.32B(-13.8%)
$662.00M(+15.7%)
$2.32B(-0.0%)
Sep 2019
-
$572.00M(+26.0%)
$2.32B(-10.8%)
Jun 2019
-
$454.00M(-27.8%)
$2.60B(-1.4%)
Mar 2019
-
$629.00M(-5.1%)
$2.64B(-1.8%)
Dec 2018
$2.69B(-2.1%)
$663.00M(-22.4%)
$2.69B(-10.3%)
Sep 2018
-
$854.00M(+73.6%)
$2.99B(+15.6%)
Jun 2018
-
$492.00M(-27.4%)
$2.59B(-3.8%)
Mar 2018
-
$678.00M(-30.1%)
$2.69B(-2.0%)
Dec 2017
$2.75B(-4.6%)
$970.00M(+116.0%)
$2.75B(+19.8%)
Sep 2017
-
$449.00M(-24.4%)
$2.29B(-32.0%)
Jun 2017
-
$594.00M(-19.0%)
$3.37B(+4.5%)
Mar 2017
-
$733.00M(+42.1%)
$3.23B(+12.1%)
Dec 2016
$2.88B(-17.9%)
$516.00M(-66.3%)
$2.88B(-32.3%)
Sep 2016
-
$1.53B(+241.5%)
$4.25B(+28.8%)
Jun 2016
-
$448.00M(+16.4%)
$3.30B(-3.4%)
Mar 2016
-
$385.00M(-79.6%)
$3.42B(-2.4%)
Dec 2015
$3.50B(+3.0%)
$1.89B(+226.6%)
$3.50B(+8.7%)
Sep 2015
-
$579.00M(+2.3%)
$3.22B(+13.4%)
Jun 2015
-
$566.00M(+20.7%)
$2.84B(-11.1%)
Mar 2015
-
$469.00M(-70.9%)
$3.20B(-6.1%)
Dec 2014
$3.40B(+0.8%)
$1.61B(+715.2%)
$3.40B(+2.6%)
Sep 2014
-
$197.50M(-78.5%)
$3.32B(-6.6%)
Jun 2014
-
$920.53M(+36.2%)
$3.55B(-0.1%)
Mar 2014
-
$675.96M(-55.6%)
$3.55B(+5.2%)
Dec 2013
$3.38B
$1.52B(+252.5%)
$3.38B(+18.2%)
Sep 2013
-
$432.00M(-53.2%)
$2.86B(-10.8%)
DateAnnualQuarterlyTTM
Jun 2013
-
$923.49M(+84.9%)
$3.20B(+0.8%)
Mar 2013
-
$499.51M(-50.2%)
$3.18B(+3.6%)
Dec 2012
$3.07B(+29.9%)
$1.00B(+29.2%)
$3.07B(+13.5%)
Sep 2012
-
$776.63M(-13.4%)
$2.70B(+9.0%)
Jun 2012
-
$897.21M(+129.8%)
$2.48B(+11.9%)
Mar 2012
-
$390.49M(-38.9%)
$2.22B(-6.2%)
Dec 2011
$2.36B(+6.7%)
$639.44M(+15.6%)
$2.36B(-4.3%)
Sep 2011
-
$553.26M(-12.5%)
$2.47B(+6.8%)
Jun 2011
-
$632.62M(+17.8%)
$2.31B(+0.4%)
Mar 2011
-
$536.88M(-28.1%)
$2.30B(+4.0%)
Dec 2010
$2.21B(-18.7%)
$746.35M(+88.4%)
$2.21B(-10.1%)
Sep 2010
-
$396.17M(-36.5%)
$2.46B(-4.2%)
Jun 2010
-
$623.55M(+39.2%)
$2.57B(+5.7%)
Mar 2010
-
$447.96M(-55.0%)
$2.43B(+3.4%)
Dec 2009
$2.72B(+17.5%)
$996.28M(+97.9%)
$2.35B(+15.7%)
Sep 2009
-
$503.55M(+3.9%)
$2.03B(+1.4%)
Jun 2009
-
$484.69M(+31.7%)
$2.00B(-3.8%)
Mar 2009
-
$368.02M(-45.6%)
$2.08B(-1.1%)
Dec 2008
$2.32B(-26.1%)
$676.71M(+42.5%)
$2.11B(+47.3%)
Sep 2008
-
$474.82M(-15.7%)
$1.43B(-11.2%)
Jun 2008
-
$563.10M(+43.9%)
$1.61B(-3.2%)
Mar 2008
-
$391.37M(-40.3%)
$1.66B(-7.4%)
Dec 2007
$3.13B(+40.5%)
-
-
Sep 2007
-
$655.49M(+6.4%)
$1.79B(+11.4%)
Jun 2007
-
$615.77M(+17.6%)
$1.61B(+21.1%)
Mar 2007
-
$523.74M(+11.1%)
$1.33B(-13.0%)
Dec 2006
$2.23B(+47.2%)
-
-
Sep 2006
-
$471.47M(+40.8%)
$1.53B(+14.3%)
Jun 2006
-
$334.75M(+10.8%)
$1.34B(+5.5%)
Mar 2006
-
$302.15M(-28.0%)
$1.27B(+6.2%)
Dec 2005
$1.51B(+5.1%)
$419.86M(+49.9%)
$1.19B(+3.9%)
Sep 2005
-
$280.13M(+5.7%)
$1.15B(-1.9%)
Jun 2005
-
$264.98M(+16.0%)
$1.17B(-4.1%)
Mar 2005
-
$228.35M(-39.1%)
$1.22B(-3.3%)
Dec 2004
$1.44B(-5.9%)
$374.65M(+24.0%)
$1.26B(+42.2%)
Sep 2004
-
$302.18M(-3.9%)
$887.18M(+51.7%)
Jun 2004
-
$314.49M(+16.3%)
$585.00M(+116.3%)
Mar 2004
-
$270.51M(-199.8%)
$270.51M(-199.8%)
Dec 2003
$1.53B(+32.4%)
-
-
Dec 2002
$1.16B(-78.1%)
-$271.12M
-$271.12M
Dec 2001
$5.27B(+97.9%)
-
-
Dec 2000
$2.66B(+100.0%)
-
-
Dec 1999
$1.33B(-0.2%)
-
-
Dec 1998
$1.34B(-35.0%)
-
-
Dec 1997
$2.05B(+34.0%)
-
-
Dec 1996
$1.53B(-25.8%)
-
-
Dec 1995
$2.06B(-7.4%)
-
-
Dec 1994
$2.23B(+7.7%)
-
-
Dec 1993
$2.07B
-
-

FAQ

  • What is Novartis AG annual capital expenditures?
  • What is the all time high annual CAPEX for Novartis AG?
  • What is Novartis AG annual CAPEX year-on-year change?
  • What is Novartis AG quarterly capital expenditures?
  • What is the all time high quarterly CAPEX for Novartis AG?
  • What is Novartis AG quarterly CAPEX year-on-year change?
  • What is Novartis AG TTM capital expenditures?
  • What is the all time high TTM CAPEX for Novartis AG?
  • What is Novartis AG TTM CAPEX year-on-year change?

What is Novartis AG annual capital expenditures?

The current annual CAPEX of NVS is $3.81B

What is the all time high annual CAPEX for Novartis AG?

Novartis AG all-time high annual capital expenditures is $5.27B

What is Novartis AG annual CAPEX year-on-year change?

Over the past year, NVS annual capital expenditures has changed by +$1.06B (+38.46%)

What is Novartis AG quarterly capital expenditures?

The current quarterly CAPEX of NVS is $578.99M

What is the all time high quarterly CAPEX for Novartis AG?

Novartis AG all-time high quarterly capital expenditures is $1.89B

What is Novartis AG quarterly CAPEX year-on-year change?

Over the past year, NVS quarterly capital expenditures has changed by -$149.01M (-20.47%)

What is Novartis AG TTM capital expenditures?

The current TTM CAPEX of NVS is $4.00B

What is the all time high TTM CAPEX for Novartis AG?

Novartis AG all-time high TTM capital expenditures is $4.25B

What is Novartis AG TTM CAPEX year-on-year change?

Over the past year, NVS TTM capital expenditures has changed by +$652.99M (+19.49%)
On this page